Moreover, that study showed a 24 percent increased risk of invasive breast cancer in women who took estrogen and progestin. Since 2002, when the WHI findings were released, the number of women using HRT has fallen sharply, but it remains the most effective treatment for menopausal symptoms and many doctors still prescribe it for short-term use. And several recent studies have suggested that breast cancer risks associated with hormone therapy may vary based on factors like body mass index (BMI) – a measure of weight in relation to height – and ethnicity. To investigate further, Huo and his team analyzed data from the National Cancer Institute’s Breast Cancer Surveillance Consortium, which includes 1,642,824 screening mammograms and 9,300 breast cancer cases. In their analysis, they looked at women 45 years old and older and considered the women’s ethnicity and BMI, as well as their breast density. Greater breast density means a woman has more breast tissue and connective tissue than fatty tissue, while lower density means she has more fatty tissue relative to breast and connective tissue.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/09/18/us-hormone-therapy-idUSBRE98H0OL20130918
Hormone replacement therapy may reduce pancreatic cancer risk
More research into how estrogen and progestin effect pancreatic cancer risk is needed, the researchers said. The new study involved more than 118,000 female public school professionals in California who were surveyed in 1995 to 1996 about their use of hormone replacement therapy and current or past use of oral contraceptives, and were followed until 2009. At the start of the study, 60 percent of the women were postmenopausal, 25 percent of whom were current users of estrogen-only HRT, and 33 percent of whom were current users of estrogen-plus-progestin HRT. During the study period, 323 women (0.27 percent) were diagnosed with pancreatic cancer. There was no link between the use of estrogen-plus-progestin HRT and pancreatic cancer risk. The age of participants at menopause, and whether they’d ever had children or breast-fed, were also not associated with pancreatic cancer risk.
For the original version including any supplementary images or video, visit http://www.foxnews.com/health/2013/09/13/hormone-replacement-therapy-may-reduce-pancreatic-cancer-risk/
Women on Hormone Therapy May Benefit From Extra Calcium, Vitamin D
Overall, the rate of hip fracture was 11 per 10,000 women per year for those who took both hormones and supplements. Women who took only hormones had a hip fracture rate of 18 per 10,000, while those who took only supplements had a hip fracture rate of 25 per 10,000. Women who received neither therapy had 22 hip fractures per 10,000 women. The researchers weren’t able to tease out whether vitamin D or calcium had any benefits on their own.
For the original version including any supplementary images or video, visit http://www.medicinenet.com/script/main/art.asp?articlekey=170820